$40.12
2.03% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Veracyte Inc Stock price

$40.12
-2.77 6.46% 1M
+18.13 82.45% 6M
+12.61 45.84% YTD
+11.69 41.12% 1Y
+0.00 0.00% 3Y
+11.02 37.87% 5Y
+30.95 337.51% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.83 2.03%
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Key metrics

Market capitalization $3.11b
Enterprise Value $2.85b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 50.55
EV/Sales (TTM) EV/Sales 6.71
P/S ratio (TTM) P/S ratio 7.31
P/B ratio (TTM) P/B ratio 2.64
Revenue growth (TTM) Revenue growth 23.95%
Revenue (TTM) Revenue $425.33m
EBIT (operating result TTM) EBIT $11.26m
Free Cash Flow (TTM) Free Cash Flow $56.48m
Cash position $274.08m
EPS (TTM) EPS $-0.14
P/E forward 111.44
P/S forward 7.00
EV/Sales forward 6.43
Short interest 3.67%
Show more

Is Veracyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Veracyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Veracyte Inc forecast:

9x Buy
75%
2x Hold
17%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Veracyte Inc forecast:

Buy
75%
Hold
17%
Sell
8%

Financial data from Veracyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
425 425
24% 24%
100%
- Direct Costs 149 149
10% 10%
35%
276 276
33% 33%
65%
- Selling and Administrative Expenses 174 174
23% 23%
41%
- Research and Development Expense 68 68
38% 38%
16%
35 35
102% 102%
8%
- Depreciation and Amortization 24 24
22% 22%
6%
EBIT (Operating Income) EBIT 11 11
187% 187%
3%
Net Profit -9.27 -9.27
81% 81%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Veracyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veracyte Inc Stock News

Positive
Investors Business Daily
17 days ago
Veracyte is in an envious position for any company — it's profitable. Veracyte stock has rocketed more than 55% this year.
Neutral
Business Wire
23 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines.
Positive
Investors Business Daily
about one month ago
Cancer diagnostics firm Veracyte has just sparked a breakout. That's just one reason to watch this AI-fueled growth stock.
More Veracyte Inc News

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marc Stapley
Employees 815
Founded 2006
Website www.veracyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today